Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder

2018 ◽  
Vol 41 (4) ◽  
pp. 220-225
Author(s):  
Gokmen U. Erdem ◽  
Mutlu Dogan ◽  
Abdullah Sakin ◽  
Zeynep Oruc ◽  
Emel Yaman ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Carcinoma Of The Bladder

Molecular profiling of non-urothelial bladder cancer: Adenocarcinoma and squamous cell carcinoma.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 423-423
Author(s):  
Daniel M. Geynisman ◽  
David Arguello ◽  
Sandeep K. Reddy ◽  
Zoran Gatalica
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Protein Expression ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumor Biology ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Histologic Subtypes ◽  
Tumor Profiling

423 Background: Adenocarcinoma (ADA) and squamous cell carcinoma (SCC) are rare and often aggressive histologic subtypes of bladder cancer. For advanced disease, no clear standard therapies exist and NCCN guidelines suggest only fluorouracil, cisplatin, paclitaxel and ifosfamide as possible options. Thus, novel therapies based on underlying tumor biology are needed. The purpose of this study was to identify potential therapeutic options for these histologic subtypes, utilizing multiplatform tumor profiling. Methods: 49 ADA and 24 SCC specimenswere tested via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) consisting of gene sequencing (Sanger or next generation sequencing [NGS]), gene amplification (CISH or FISH), and protein expression (immunohistochemistry [IHC]). 52% of cases were from metastatic sites. Results: Both ADA and SCC exhibited high rates of TP53 aberrations (82.4% and 72.7%, respectively). Sequencing revealed mutations in BRCA2 (14.3%), SMAD4 (12.5%), PTEN (11.8%), KRAS (8.7%), NRAS (5.6%), and KIT (5.3%) in ADA. In addition, PIK3CA (21.4%), HRAS (18.2%), BRCA1 (16.7%), BRCA2 (16.7%), and FBXW7 (9.1%) mutations were detected in SCC. Amplification in EGFR (27.3%) and ERBB2/HER2 (16.7%) were found in ACA. Meanwhile, only one ERBB2 (6.3%) amplification was found in SCC using ISH. MET was not amplified in either ACA or SCC. For both ACA and SCC, EGFR had the highest level of protein expression (100% and 85.7%, respectively). Of note, PD-1 (44.4% in both) and PD-L1 (11.1% and 22.2% in ACA and SCC, respectively) were expressed in both subtypes. Although differential rates of somatic alterations, amplification, and protein expression were found between ADA and SCC, only TLE3 was significant (19.2% versus 60.0%, respectively, p = 0.0154). Conclusions: Differential results in gene alteration, amplification, and protein expression imply the potential utility of tumor profiling in guiding therapeutic decision-making in ADA and SCC of the bladder. PIK3CA/AKT/mTOR pathway aberrations are similar to what has been reported in urothelial bladder cancer. Targeting the PD-1/PD-L1 axis may be a therapeutic option. Further studies are warranted in both diseases.

scholarly journals Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer

2013 ◽  
Vol 3 (6-S4) ◽  
pp. 193 ◽  
Author(s):  
Venu Chalasani ◽  
Joseph L. Chin ◽  
Jonathan I. Izawa
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Urothelial Cancer ◽  
Small Cell ◽  
Urothelial Bladder Cancer ◽  
Divergent Differentiation ◽  
Urothelial Bladder ◽  
Worse Prognosis

Bladder cancer can be classified histologically as urothelial ornon-urothelial. Urothelial cancer has a propensity for divergentdifferentiation, which has increasingly been recognized in recentyears due to heightened awareness and improved immunohistochemistrytechniques. Furthermore, the recent World HealthOrganization classification of urothelial cancers improved clarityon this issue, with its listing of 13 histologic variants of urothelialcancer. The divergent differentiation patterns include, amongstothers, squamous, glandular, micropapillary, nested, lymphepithelioma-like, plasmacytoid and sarcomatoid variants of urothelialcancer. Attempts to quantify the amount of divergent differentiationpresent, such as using the nonconventional differentiationnumber, have been made recently, which will improve the abilityto compare publications from different centres. Genetic-basedstudies have indicated that the histologic variants of urothelialcancer arise from a common clonal precursor. Mostly, the currentevidence suggests that urothelial cancer with divergent differentiationhas a worse prognosis when compared with pure urothelialcancer. This article will review the current literature on varianthistologies of urothelial cancer, and well as new developmentsin pure squamous cell carcinoma, small cell carcinoma and adenocarcinomaof the bladder.

scholarly journals Primary non-urothelial squamous cell carcinoma masquerading as a perforated gastric ulcer: a case report

2019 ◽  
Vol 2019 (7) ◽  
Author(s):  
Rachel E Kaczynski ◽  
Daniel Fegely ◽  
Matthew Nier ◽  
Neysa Valentin-Capeles ◽  
Jackie Battista
Keyword(s):  
Squamous Cell Carcinoma ◽  
Gastric Ulcer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Incidental Finding ◽  
Exploratory Laparotomy ◽  
Rare Form ◽  
Urothelial Bladder ◽  
Carcinoma Of The Bladder ◽  
High Risk Hpv

Abstract We present an 84-year-old female patient with a very rare form of primary non-urothelial squamous cell carcinoma of the bladder, found incidentally during emergency exploratory laparotomy for a perforated pre-pyloric gastric ulcer. The bladder tumor was positive for CK5/6, CK903, and thrombomodulin biomarkers, as well as for high-risk HPV (16, 18, and 31). Based on a literature review of non-urothelial bladder cancers, specifically non-bilharzial squamous cell carcinoma, we believe our patient had a very rare form of primary non-urothelial squamous cell carcinoma of the bladder. The presence of these tumor markers and the lack of clinical evidence to suggest another primary origin, such as anus, rectum, cervix, or uterus, support this conclusion. This case provides an interesting example of a very rare incidental finding during an emergent procedure.

scholarly journals Bladder squamous cell carcinoma in a pregnant woman: case report and review of the literature

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Pablo A. Rojas ◽  
Cristián González ◽  
Gonzalo P. Mendez ◽  
Alejandro Majerson ◽  
Ignacio F. San Francisco
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Pregnant Woman ◽  
Urinary Tract ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Squamous Cell ◽  
Pet Ct ◽  
Cell Bladder Cancer ◽  
Urinary Tract Reconstruction

Abstract Background Bladder tumors in pregnancy are extremely rare. No more than 50 cases have been published to date, including all histologic variants, and only three cases of bladder squamous cell carcinoma have been described. Case presentation We present a clinical case of a 31-year-old woman with bladder squamous cell carcinoma in the second trimester of pregnancy. After a C-section at 30 weeks, we performed radical cystectomy with extended bilateral lymphadenectomy, hysterectomy and right oophorectomy. The Studer neobladder technique was performed for urinary tract reconstruction. Definitive pathology showed invasive bladder squamous cell carcinoma, Grade 2, with microscopic infiltration of the perivesical fat, negative margins, and 3/28 lymph nodes with carcinoma (pT3aN2M0). The patient underwent 18 months of surveillance after radical cystectomy, without recurrence by PET-CT. Conclusions Bladder cancer in pregnant women is extremely rare but must be considered in those with recurrent gross hematuria and/or recurrent urinary tract infection. To our knowledge, this case involves the longest recurrence-free survival of a pregnant woman with squamous cell bladder cancer published thus far.

scholarly journals Robot-assisted Diverticulectomy for an early-stage squamous cell carcinoma of the bladder

2021 ◽  
Vol 33 ◽  
pp. S115
Author(s):  
G. Pignot ◽  
V. Lorusso ◽  
A. Le Quellec ◽  
A. Pacchetti ◽  
C. Rion ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Early Stage ◽  
Robot Assisted ◽  
Carcinoma Of The Bladder

Urinary tract infections and risk of squamous cell carcinoma bladder cancer: A Danish nationwide case–control study

2020 ◽  
Vol 146 (7) ◽  
pp. 1930-1936 ◽  
Author(s):  
Anton Pottegård ◽  
Kasper B. Kristensen ◽  
Søren Friis ◽  
Jesper Hallas ◽  
Jørgen B. Jensen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Urinary Tract ◽  
Cell Carcinoma ◽  
Urinary Tract Infections ◽  
Squamous Cell ◽  
Case Control Study ◽  
Case Control ◽  
Tract Infections ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document